

Mariano Severgnini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/853551/publications.pdf>

Version: 2024-02-01

31
papers

1,175
citations

623734

14
h-index

642732

23
g-index

31
all docs

31
docs citations

31
times ranked

2519
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	4.1	170
2	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
3	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	3.4	130
4	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	3.4	81
5	Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. , 2020, 8, e000678.		78
6	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
7	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	6.4	66
8	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
9	A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2470-2480.	7.0	51
10	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2209-2221.	4.2	32
11	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. <i>OncImmunology</i> , 2018, 7, e1440930.	4.6	30
12	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021, 39, 380-393.e8.	16.8	27
13	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
14	High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. <i>STAR Protocols</i> , 2020, 1, 100055.	1.2	19
15	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	12.8	19
16	Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2991-3000.	4.2	18
17	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
18	Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients. <i>Cell and Tissue Banking</i> , 2018, 19, 783-790.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	3.7	15
20	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. <i>Journal of Biological Methods</i> , 2019, 6, e114.	0.6	14
21	Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. , 2021, 9, e002472.		13
22	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. <i>Blood Advances</i> , 2021, 5, 4701-4709.	5.2	12
23	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	5.2	12
24	Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. <i>Cytotechnology</i> , 2018, 70, 1-11.	1.6	11
25	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
26	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7
27	Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. <i>Journal of Biological Methods</i> , 2020, 7, e131.	0.6	6
28	Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix. <i>Blood</i> , 2021, 138, 2539-2539.	1.4	5
29	Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling. <i>Immunotherapy</i> , 2022, 14, 843-850.	2.0	3
30	Mass cytometry staining for human bone marrow clinical samples. <i>STAR Protocols</i> , 2022, 3, 101163.	1.2	1
31	Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials. <i>STAR Protocols</i> , 2022, 3, 101362.	1.2	1